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Bordetella pertussis, the causative agent of whooping cough, has 
many well-studied virulence factors and a characteristic clinical 
presentation. Despite this information, it is not clear how B. 
pertussis interaction with host cells leads to disease. In this study, 
we examined the interaction of B. pertussis with a human bronchial 
epithelial cell line (BEAS-2B) and measured host transcriptional 
profiles by using high-density DNA microarrays. The early tran- 
scriptional response to this pathogen is dominated by altered 
expression of cytokines, DNA-binding proteins, and NFKB-regu- 
lated genes. This previously unrecognized response to B. pertussis 
was modified in similar but nonidentical fashions by the antiin- 
flammatory agents dexamethasone and sodium salicylate. Cyto- 
kine protein expression was confirmed, as was neutrophil che- 
moattraction. We show that B. pertussis induces mucin gene 
transcription by BEAS-2B cells then counters this defense by using 
mucin as a binding substrate. A set of genes is described for which 
the catalytic activity of pertussis toxin is both necessary and 
sufficient to regulate transcription. Host genomic transcriptional 
profiling, in combination with functional assays to evaluate sub- 
sequent biological events, provides insight into the complex in- 
teraction of host and pathogen. 
B ordetella pertussis is a Gram-negative coccobacillus and the 
causative agent of whooping cough in humans. It is a 
well-studied pathogen with a number of potent virulence factors. 
However, little is known about the responses elicited by this 
organism in human cells, especially at the level of gene 
transcription. 
Autopsy studies of pertussis victims performed in the early 20th 
century revealed a diffuse bronchopneumonia with increased se- 
cretion of mucus, associated with airway plugging and atelectasis 
(1). Bacteria were seen tightly packed between the cilia of epithelial 
cells, which desquamated during infection. Rodent models of 
Bordetella pertussis infection have revealed infiltrates of monocytes, 
neutrophils, and lymphocytes in the lung (2). 
B. pertussis expresses several virulence factors directed at the 
host epithelium. Filamentous hemagglutinin isthe major adhesin 
of B. pertussis for bronchial epithelial cells (3). B. pertussis also 
produces several toxins, including pertussis toxin (PT). PT is 
associated with a panoply of biological effects, many of which are 
linked to its ADP-ribosyltransferase activity. ADP ribosylation 
of the Ga family of host proteins prevents their usual regulatory 
response to G-protein-linked receptor engagement (4). B. per- 
tussis also secretes an adenylate cyclase toxin that enters host 
cells and raises intracellular cAMP concentrations (5). Tracheal 
cytotoxin (TCT), a muramyl tetrapeptide bacterial cell wall 
fragment, in combination with lipopolysaccharide, paralyzes 
respiratory epithelial cilia and ultimately causes cell death and 
extrusion through pathways involving IL-1 and nitric oxide 
synthase (iNOS) (6). The molecular mechanisms through which 
B. pertussis exerts these effects and by which host cells attempt 
to counter this pathogenic strategy remain largely undescribed. 
The goal of this study was to understand the pathology caused 
by B. pertussis and to explore whether early transcriptional 
responses reveal pathogenic mechanisms and pathology at a 
molecular level. Our approach involved genome-wide xpression 
analysis of a human bronchial epithelial cell line exposed to B. 
pertussis, coupled with functional analyses. 
Materials and Methods 
Bacterial Strains, Toxins, and Cell Lines. Wild-type B. pertussis BP536 
(3) and an isogenic derivative xpressing a catalytically inactive PT, 
BP-9K/129G (7), were grown at 37?C on Bordet-Gengou agar 
(Difco), supplemented with sheep blood (13% v/v) and 100 ,tg/ml 
streptomycin. Bordetellae were suspended in Eagle's minimal 
essential medium (EMEM) without FCS overnight at 37?C in 5% 
CO2. They were then added to 2 x 107 epithelial cells at a ratio of 
50 bacteria per cell. Purified wild-type and catalytically inactive PT 
(7) were added to 2 x 107 epithelial cells at a concentration of 1 
Ag/ml. The SV40-transformed human bronchial epithelial cell-line 
BEAS-2B (8) was grown in EMEM with 10% FCS at 37?C in 5% 
CO2. A human colon carcinoma cell line, HM3, was stably trans- 
fected with a construct of the MUC2 or MUC5AC promoter fused 
to a luciferase reporter gene. Transfected cells were maintained in 
DMEM with high glucose and 10% FCS. 
Infection Scheme. BEAS-2B cells (1-1.5 x 107) were incubated for 
8 h, then some were treated for 1 hr with 10 mM sodium 
salicylate or 1 ,tM dexamethasone. The cells were then infected 
with B. pertussis, exposed to PT, or mock infected, and incubated 
at 37?C for 3 h. Cells were washed with Hanks' balanced salt 
solution (HBSS), released from the flask with 5 mM EDTA in 
HBSS, pelleted at 200 x g for 5 min and frozen at -80?C. 
Microarray Expression Analysis. Total RNA was extracted from cell 
pellets by using Trizol (Life Technologies, Rockville, MD) and 
purified by using an affinity resin (RNeasy, Qiagen, Chatsworth, 
CA). Microarray analysis was performed according to the Af- 
fymetrix Expression Analysis Technical Manual with the follow- 
ing exceptions (see http://relman.stanford.edu): first-strand 
cDNA synthesis was performed at 42?C, and 10 ptg of total RNA 
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Table 1. Epithelial cell transcriptional profile after exposure to B. pertussis 
Down-regulated transcripts Up-regulated transcripts 
Ratio Accession no. GDB/other names Ratio Accession no. GDB/other names 
Chemokines/Cytokines 
+22.38 X54489 GRO1/SCYB1/MGSA 
+16.29 M28130 IL8 
+9.11 Y00787 IL8 
+6.80 X04500 IL1 B 
+6.47 N/A MCP1 /SCYA2 
M57731 GRO2/SCYB2/MIP-2a 
X04602 IL6/IFNB2 
M23178 SCYA3/MIP-1a 
X53800 GRO3/SCYB3/MIP-2a 
Transcription factors/Zn-finger p oteins 
-3.03 X51435 ZNF40/HIVEP1 +7.39 M59465 TNFAIP3/A20 
D88613 HGCM/GCMA X65663 SOX6 
U 10324 ILF3/NF90 M82882 ELF1/E74-like factor 
N/A MYBL1/A-MYB U69127 FUBP3/(FUSE)-binding protein 3 
X59244 ZNF43/zinc-finger p otein U 18259 MHC2TA/CIITA-8 
X55544 ATF1/TREB36 
M29581 ZNF8/zinc-finger p otein 8 
M96843 ID2/inhibitor DNA binding 
U78722 ZNF165/zinc-finger p otein 
U28687 ZNF157/zinc-finger p otein 
N/A BTF3 homologue 
Secreted molecules 
U19557 SCCA2/protease Inhibitor +4.59 M57730 EFNA1/LERK1/B61/Ephrin Al 
U90546 BTN3A2/butyrophilin M31166 PTX3/pentaxin-related/TSG-14 
X64877 HFL3/H factor complement X57579 INHBA/inhibin, f A/activin 
S75256 LCN2/lipocalin 2 X75308 MMP13/collagenase 3 
M21642 AT3/antithrombin III M31551 PAI2/plasminogen active inhibitor 
ER/Golgi associated 
X97064 SEC23A L10333 RTN1/reticulon 1 
X71661 LMAN-1 /ERGIC-53/lectin U27326 FUT3/fucosyltransferase 3 
L41 390 acetylglucosaminyltransfer 
U14550 STHM/sialyltransferase 
Metabolic/synthetic 
-3.44 AC002115 COX6B/cytochrome c oxid. D38524 Cytosolic purine 5'-nucleotidase 
M61853 CYP2C17/P45011C17 X78711 GK/glycerol kinase deficiency 
M60891 UROD/decarboxylase M61855 CYP2C9/cytochrome P450, Ilc 
D49488 TTPA/tocopherol a transfer Z94753 ATP7A/Cu++ ATPase 
U75362 USP13/ubiquitin protease 
S72370 PC/pyruvate carboxylase 
X59834 GLUL/glutamine synthase 
M84424 CTSE/cathepsin E
M64082 FMO1/monooxygenase 1 
D28791 PIGA/phosphate inositol glycan 
D10040 FACL1/fatty-acid-coA ligand 
Cell surface molecules/Receptors 
-4.76 M32315 TNFRSF1 B/TNF receptor 2 +4.53 Y00285 IGF2R/IGF IIreceptor 
-3.85 N/A PSG1 1/glycoprotein +4.30 M24283 ICAM1/CD54 
L36531 ITGA8/integrin alpha 8 +3.27 U92971 F2RL2/thrombin receptor-like 
M23197 CD33 S59184 RYK/receptor tyrosine kinase 
U64871 GPR19/G protein-coupled K02405 HLA-DQB1/HLA-DC-3 f 
U04811 TRO/Trophinin U11878 CXCR2/IL8RB/IL-8 receptor 
Y09392 TNFRSF12/APO-3/TNFR U65011 PRAME/antigen of melanoma 
X1 6983 ITGA4/CD49D/integrin 
U61500 TMEM1/EHOC-1 
X77753 M1S1/TROP-2/GA733-1 
S67798 SPAM1/sperm adhesion 
D31784 CDH6/cadherin-6 
S83249 NG-TRA/hormone pump 
U8081 1 EDG2/G-protein-coupled 
Cytoskeleton 
L07261 ADD 1/a adducin 1 L20826 PLS1/l-plastin 
U34301 Nonmuscle myosin heavy chain 
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Table 1. Continued 
Down-regulated transcripts Up-regulated transcripts 
Ratio Accession no. GDB/other names Ratio Accession no. GDB/other names 
Intracellular signaling 
U48736 PRP4h/ser-thr p otein kinase +3.47 L42373 PPP2R5A/protein phosphatase 
M38258 RARG/retinoic a id receptor +3.27 M69043 NFKBIA/IKBA/MAD-3 
U 18671 STAT2 U77129 MAP4K5/KHS1/kinase 
M35416 RALB/v-ral homolog B M80563 S100A4/CAPL calcium binding 
U40371 PDE1 C/phosphodiesterase U37546 API2/1AP homolog C/MIHC 
U77845 hTRIP/TRAF-interacting 
X78549 PTK6/BRK 
U20158 LCP2/SLP-76 
U17327 NOS1/nitric oxide synthase 
DNA replication/transcription 
U01833 NUBP1/nucleotide binding +3.31 N/A POLE/DNA polymerase, e
U47414 CCNG2/cyclin G2 X54993 TBP/TFIID/TATA box binding 
D26528 DDX7/RNA helicase X95152 BRCA2/breast cancer 2 
The experiment was repeated twice independently; data from one experiment are shown. Absolute difference ratios above or below the uninfected 
transcription are not reported when one of the two values was less than 2-fold the background noise level. 
was used. Triton X-100 (0.01%) was used in hybridization 
solutions and buffers instead of Tween 20. Labeled cRNA (20 
,tg) was hybridized to Affymetrix HU6800 GENECHIP microar- 
rays (Affymetrix, Santa Clara, CA) for 18 h in buffer without 
EDTA. The arrays were rinsed with 6x standard saline phos- 
phate/EDTA (SSPET, 0.18 M NaCI/10 mM phosphate, pH 
7.4/1 mM EDTA), washed in 0.1X Mes at 50?C for 30 min on 
a rotisserie at 60 rpm, and then rinsed in 1x Mes. Hybridized 
RNA was fluorescently labeled by incubation in streptavidin- 
R-phycoerythrin conjugate (Molecular Probes) staining buffer 
at 40?C for 15 min, then washed with 6X SSPET at 22?C. 
Quantitative analysis of hybridization patterns and intensities 
were performed as previously described (9) (see http:// 
relman.stanford.edu). 
Cytokine and Apoptosis Quantitation. For cytokine analysis, 96-well 
plates were coated with 0.2 jig of capture mAb (MAB 279, 206, 
208, R&D Systems) and then blocked with 1% BSA in PBS. One 
hour later, 10 ng of a biotinylated polyclonal Ab (BAF 279, 206, 
208, R&D Systems) was added for 1 h. After washing, bound Ab 
was detected by using a streptavidin-horseradish peroxidase 
conjugate and tetramethylbenzadine substrate. Cytoplasmic 
histone-associated DNA fragments were quantitated as a mea- 
sure of apoptosis by using the Cell Death Detection ELISA Plus 
kit per manufacturer ecommendations (Roche Diagnostics). 
Neutrophil Chemotaxis. Whole human blood was mixed 1:1 with 
dextran in PBS for 45 min at 25?C. The top layer was overlaid on 
Ficoll-Paque (Amersham Pharmacia) and centrifuged at 450 x g 
for 45 min, then granulocytes were harvested. RBCs were lysed 
in hypotonic saline. Neutrophil purity was >95%. One hundred 
thousand neutrophils were placed on a 3-,tm filter (Neuroprobe, 
Cabin John, MD) separating them from 29 ,tl of BEAS-2B 
supernatant in a 96-well microchamber. In some wells, anti- 
human IL-8 Ab was added at 10 ,ug/ml for the duration of the 
experiment (MAB208, R&D Systems). After 1 h at 37?C, only 
cells that had passed through the filter were quantified by using 
the CyQuant Cell Proliferation Kit (Molecular Probes). 
Mucin Transcription a d Binding. HM3 cells (1.5-3 x 106) carrying 
either a MUC2 or MUC5AC promoter fusion to a luciferase 
reporter gene were infected with B. pertussis in DMEM without 
FCS in triplicate. After 2, 4, and 6 h, the cells were lysed for 30 
min with 100 ,ul Reporter Lysis Buffer (Luciferase Assay System, 
Promega) and then frozen at -80?C. The luciferase assay was 
carried out per manufacturer ecommendations. 
For binding, 2.5 ,tg of bovine submaxillary mucin type I-S 
(Sigma) was desiccated onto a microtiter plate at 37?C. Mucin- 
treated and -untreated plates were then washed with PBS and 
blocked with 5% dried nonfat milk in PBS for 1 h at 37?C and again 
washed with PBS. A suspension of B. pertussis labeled with a 
250-Ag/ml solution of FITC for 20 min was then added to the plates 
for 1 h. Approximately 2.5 x 108 of labeled bacteria were added per 
well. Nonadherent bacteria were washed away with three cycles of 
PBS washings. Plates were then read in a 96-well fluorimeter. 
Results 
The Transcriptional Profile of BEAS-2B Cells Infected with B. pertussis 
Reveals the Basis of Inflammation i Pertussis. Although the pathol- 
ogy of pertussis has been studied for decades, little is known about 
the response of individual cell types to infection. We examined the 
genome-wide transcriptional responses of a bronchial epithelial cell 
line, BEAS-2B (8), after infection with a wild-type B. pertussis strain 
(BP536) for 3 h. Preliminary analyses had shown more robust 
responses after 3 h than after 1 h (data not shown). Steady-state 
transcript abundance for approximately 6,800 human genes was 
analyzed in duplicate experiments. Reproducibility of the data was 
examined by using duplicate preparations of labeled cDNA/cRNA 
from RNA isolated from each of two replicate infection experi- 
ments. These analyses revealed 19.5% and 26.9% variation in mean 
average difference values for all probe sets in the four comparisons. 
The complete data sets for these (Table 2) and other experiments 
(Tables 3-8) are available at http://relman.stanford.edu. 
Table 1 categorizes the named BEAS-2B genes that exhibited 
greater than a 3-fold change in steady-state transcript abundance 
after 3 h of infection. These results are noteworthy for the modest 
number of genes that responded to B. pertussis exposure, unlike the 
responses observed at later time points during human cytomega- 
lovirus (10) and HIV-1 infections (J. Corbeil, D. Genini, D. 
Sheeter, S. Rought, L. Leoni, P. Du, M. Ferguson, D. R. Masys, J. B. 
Welsh, J. L. Fink, et al., personal communication). Of the 33 genes 
whose expression levels increased in abundance by greater than 
3-fold on B. pertussis infection, the most well-represented category 
(8) was a group encoding proinflammatory c tokines. None of 
these had been previously implicated in B. perttussis infection, but 
their known chemoattractant activities are consistent with the 
cellular infiltrate s en in pertussis. Our data also revealed increased 
IL-113 transcription. IL-1 is known to increase growth-regulated 
oncogene (GRO) mRNA and has been shown to play a role in 
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TCT-mediated respiratory epithelial cell toxicity (11, 12). Other 
up-regulated gene products, such as IKB, are involved in NFKB 
signaling and may regulate these cytokines (13). 
The data in Table 1 reveal regulation of several apoptosis-related 
genes. TNFAIP3 and API2 are antiapoptotic factors whose genes 
are transcriptionally up-regulated by infection (14, 15). Further- 
more, transcription of BTF3, a transcription factor associated with 
apoptosis, is decreased (16). Given that monocytes and neutrophils 
have been described to undergo apoptosis in response to B. pertussis 
infection (17), we looked for evidence of apoptosis in B. pertussis- 
infected BEAS-2B cells by using an ELISA assay for mono- and 
oligonucleosomes at the 3-h time point used in the microarray 
experiments. Representative data from duplicate experiments re- 
vealed no evidence of apoptosis [absorbance of 0.028 ? 0.005 
(mean ? 95% confidence interval) for the infected cells and 
0.029 ? 0.005 for the uninfected cells (P = 0.85)]. 
The 65 genes whose expression levels decreased by greater 
than 3-fold included those encoding 10 transcription factors and 
6 cellular adhesion molecules. The overall transcriptional profile 
of these infected cells suggested a picture of relatively rapid 
activation and defensive host responses. 
The ADP-Ribosyltransferase Activity of PT Is Responsible for Specific 
Transcriptional Responses. To define the role of PT ADP-ribosylase 
activity at the transcriptional level, we compared the responses of 
BEAS-2B cells to two pairs of stimuli: (i) wild-type PT vs. a 
catalytically inactive but properly folded PT holotoxin (9K/129G), 
and (ii) wild-type B. pertussis vs. an isogenic derivative that ex- 
presses PT-9K/129G. Data sets are available as Tables 3 and 4 at 
http://relman.stanford.edu; Table 5 lists genes whose expression 
changed more than 3-fold when comparing the effects of both the 
purified inactive toxin with wild-type toxin and the toxin-mutant 
strain with its isogenic parent strain. Thus, these host cell genes 
represent hose for which pertussis toxin enzymatic activity was 
both necessary and sufficient o effect a change in transcript 
abundance. Several of these genes are G-protein or cAMP regu- 
lated, such as those encoding matrix metalloproteinase 1, 13 Bi- 
crystallin, basic fibroblast growth factor, and the Na+/Cl-- 
dependent serotonin transporter. Surprisingly, other genes such as 
the serum/glucocorticoid-regulated kinase, whose expression level 
decreased, and guanylate cyclase 1, whose expression level in- 
creased, showed responses in directions contrary to those suggested 
by the literature. The majority of the PT-response genes revealed 
in these experiments had not been previously associated with 
G-protein activity. Thirty-eight genes with discordant 3-fold 
changes, suggesting an effect of PT activity that depends on other 
bacterial factors, are highlighted (Table 6) at http://relman. 
stanford.edu. 
The Chemokine Response of B. pertussis-Infected Epithelial Cells 
Overcomes the Antichemotactic A tivity of PT. The known activities 
of PT and other B. pertussis virulence factors such as adenylate 
cyclase toxin suggest that they might be capable of blocking the 
chemotactic response predicted by our data (18). We first docu- 
mented the predicted protein expression responses for several of 
the cytokine genes that were induced in BEAS-2B cells. Fig. la 
shows an increase in secreted IL-8 from 35 ? 0.8 (mean ? 95% 
confidence interval) to 678 ? 78 ng/ml (P = 0.0006) and MCP-1 
from 580 ? 29 to 3367 ? 349 ng/ml (P = 0.004) (Fig. lb) when the 
supernatants of BEAS-2B cells were harvested after 24 h of 
exposure to B. pertussis or mock infection. Induction of IL-6 
secretion was also confirmed, with none detectable in uninfected 
supernatants, whereas 116 ? 2 ng/ml was detected in supernatants 
from infected cells (P < 2.5 x 10-7) (Fig. lc). 
IL-8 and the GRO family of chemokines are strong neutrophil 
chemoattractants hat have not been previously associated with B. 
pertussis infection (19, 20). We examined the chemoattractant 
activity of the BEAS-2B cell supernatants by using a neutrophil 
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Fig. 1. (a-c) Changes in secreted chemokine abundance after exposure of an 
epithelial cell line to B. pertussis for 24 h. Representative data from duplicate 
experiments are shown. Assays were performed for IL-8 (a), MCP-1 (b), and IL-6 
(c). (d) Migration of neutrophils in responseto the supernatants of B. pertussis- 
infected epithelial cells. In duplicate experiments, neutrophils migrated to- 
ward the supernatant with or without 10 jig/ml anti-IL-8 Ab. Migration index 
is the ratio of cells that migrated to a supernatant in comparison to the 
uninfected supernatant. Error bars represent he 95% confidence interval of 
the mean of three wells. 
migration assay, in which cells are separated from BEAS-2B 
supernatants by a porous membrane. As shown in Fig. Id, 2.9-fold 
more neutrophils were attracted to the supernatant of infected cells 
than to that of uninfected cells. Furthermore, cell migration could 
be partially inhibited (34% with the infected cell supernatant) by 
using an anti-IL-8 mAb, suggesting that IL-8 contributes to this 
chemoattractant activity and indicating a role for other chemokines 
as well. Although previous reports suggest that PT is capable of 
inhibiting neutrophil chemotaxis in vitro (21), chemoattraction was 
the dominant effect in this experimental system. 
Antiinflammatory Drugs Suppress the Epithelial Cell Responses to B. 
pertussis. The data presented above and in Table 1 reveal up- 
regulation of genes whose products play a role in NFKB activation 
as well as genes known to be regulated by NFKB. We hypothesized 
that pretreatment of the epithelial cells with antiinflammatory 
drugs that interfere with NFKB activation could help confirm 
mechanisms by which B. pertuissis stimulates a proinflammatory 
cellular response. Dexamethasone was chosen because glucocorti- 
coids have been suggested as a therapy for pertussis, despite the 
paucity of supportive data (22). Glucocorticoids may inhibit NFKB 
activity by augmenting IKB synthesis or through association of their 
bound receptors to NFKB (23). Sodium salicylate inhibits NFKB 
activation of genes by preventing phosphorylation of IKB (24). 
The transcriptional responses of BEAS-2B cells pretreated with 
either sodium salicylate or dexamethasone and then exposed to B. 
pertussis BP536 differed profoundly from untreated cells (Tables 7 
and 8, http://relman.stanford.edu). Pretreatment eliminated the 
infection-associated induction of GRO-2, GRO-1, IL-8, IL-6, IL- 
13, MCP-1, MIP-la, GRO-3, CIITA, HLA-DQ, API2/IAP, and 
other genes that were induced in untreated cells. However, differ- 
ences were also noted in the effects of these two inhibitors. 
Dexamethasone failed to block a 2.9-fold infection-associated in- 
duction of the antiapoptotic molecule TNFAIP3, whereas salicylate 
was inhibitory. Furthermore, dexamethasone pretreatment led to a 
4.8-fold infection-associated increase in expression of iNOS, which 
was not seen in salicylate-pretreated cells or in the absence of drug 
pretreatment. Transcription of IL-1, which has been implicated in 
13850 | www.pnas.org Belcher et al. 
the induction of iNOS activity (12), was not detected in dexa- 
methasone-treated cells. 
B. pertussis Binds Mucin and Induces Its Expression by Bronchial 
Epithelial Cells. The regulated expression of mucin in the respi- 
ratory tract is one innate host defense that respiratory pathogens 
must overcome. Given previously published evidence of mucin 
gene responses to other respiratory noxious stimuli, we examined 
our microarray expression data for responses by the mucin gene 
family. MUC2, which encodes a respiratory tract mucin glyco- 
protein, was expressed at 1.5-fold increased levels in cells 
exposed to B. pertussis, whereas no response was noted for MUC3 
(encodes intestinal mucin) and MUC6 (encodes gastric mucin). 
These data prompted further investigation by using a system that 
is more sensitive to small changes in mucin gene transcriptional 
activity. MUC2 and MUC5AC [also shown to be transcribed in 
respiratory epithelium (25)] were studied by using epithelial cells 
that harbor a stable transfected copy of the MUC2 or MUC5AC 
promoter fused to a luciferase reporter gene. Transcription of 
MUC2 and MUC5AC increased during the experiment in both a 
dose- and time-dependent manner (Fig. 2 a and b). At 6 h, the 
highest bacterial dose gave 32-fold (P = 0.002) and 17-fold (P = 
0.01) increases in MUC2- and MUC5AC-luciferase activities, 
respectively. To our knowledge, there have been no previous 
descriptions of mucin gene responses to B. pertussis infection. 
Given the ability of B. pertussis to induce mucin gene transcrip- 
tion, we hypothesized that the bacterium might be capable of 
binding mucin. Fig. 2c shows that B. pertussis adhered to microtiter 
plates at 4-fold higher levels when the wells were coated with bovine 
salivary mucin and then treated with a nonspecific blocking agent 
(nonfat dry milk) than they did to wells treated with the blocking 
agent alone (P < 6 x 10-12). A related species, Bordetella bron- 
chiseptica has been shown to bind to swine nasal mucosa sialyl 
glycoconjugates, including mucin (26). Evaluation of several glyco- 
conjugates revealed that a sialic acid-containing anglioside mix- 
ture was able to inhibit B. pertussis binding to mucin by 32% (P < 
0.005). N-acetyl-neuraminic acid blocked binding better than N- 
acetyl-D-glucosamine, but neither produced a significant decrease 
(22% and 12%, P values of 0.07 and 0.32, respectively). These data 
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Fig. 2. (a and b) Induction of mucin repor-ter genes by B. pertussis nfection. In 
duplicate xperiments, anepithelial cell line carrying a mucin-luciferase reporter 
gene fusion was exposed to varying numbers of B. pertussisfor increasing periods 
of time. Representative data from one experiment inwhich the fusion contained 
the promoter from MUC2 (a) or the promoter from MUC5AC (b) are shown. (c) 
Binding of B. pertussis to mucin-coated plates. One set of data from triplicate 
experiments hat demonstrates binding of B. pertussis to mucin-coated and 
blocked wells vs. those coated with blocking agent alone. Background fluores- 
cence of the mucin and nonfat milk are demonstrated by the third and fourth 
bars. Error bars represent the 95% confidence interval. 
suggested that binding of B. pertussis to mucin is mediated by sialic 
acid-containing compounds. 
Discussion 
The use of high-density DNA microarrays to survey genome- 
wide transcriptional responses in host cells after exposure to 
microbial pathogens is a powerful approach to understanding 
host-pathogen interactions (10, 27, 28) (J. Corbeil, D. Genini, D. 
Sheeter, S. Rought, L. Leoni, P. Du, M. Ferguson, D. R. Masys, 
J. B. Welsh, J. L. Fink, et al., personal communication). Our data 
provide an overview of the interaction between B. pertussis and 
respiratory epithelial cells at the level of gene transcription and 
suggest a number of testable hypotheses. Our studies have 
revealed a dominant proinflammatory state in B. pertussis- 
exposed bronchial epithelial cells and the induction of host 
defenses that might be coopted or subverted by this pathogen. In 
addition, we have documented responses by a number of genes 
that were not previously known to be associated with B. pertussis 
or its virulence factors. 
As with any model system, our experimental design and data 
have limitations. Transformed cell lines may respond in a manner 
distinct from that of primary cells by virtue of altered controls on 
growth and differentiation. Furthermore, we are limited by data 
from only a single time point and a single multiplicity ofinfection. 
Our system is also limited by the presence of only one cell type, 
whereas in an infected host, the responses of bronchial epithelial 
cells would be modified by the presence of other immune and 
nonimmune cells and a wide variety of soluble factors. These 
limitations were accepted to create an easily controlled, easily 
manipulated, and reproducible model of the interaction between 
B. pertussis and its primary target cell. 
B. pertussis-Infected Bronchial Epithelial Cells Exhibit a Transcrip- 
tional Profile Dominated by a Proinflammatory Response. Eight of the 
thirty-three g nes that met our induction criteria on B. pertulssis 
infection encode proinflammatory c tokines. This host response 
profile has not been described previously for B. pertussis infection. 
Although the chemokines IL-8, GRO-1, GRO-2, and GRO-3 are 
strong neutrophil chemoattractants, MCP-1 and SCYA3 promote 
monocyte infiltration (19, 20, 29). IL-8, GRO-1, and SCYA3 have 
also been shown to exert lymphocyte chemoattractant properties 
(30, 31). These results help to explain the infiltrate s en in autopsy 
studies of humans with pertussis and in animal models of the disease 
(1, 2). Furthermore, IL-8, MCP-1, and GRO-1 are known to 
promote expression of CD11b/CD18 (CR3) on the surface of 
neutrophils and monocytes (32, 33). This leukocyte integrin is a 
receptor for the major adhesin of B. pertussis, filamentous hemag- 
glutinin (34). However, the binding of B. pertussis to leukocytes is 
not necessarily detrimental to this pathogen: the organism inhibits 
oxidative burst and intracellular killing and instead up-regulates its 
own binding to these cells and inhibits antigen-dependent T cell 
proliferation (34, 35). This suggests B. pertussis has adapted to the 
inflammatory response that it elicits from bronchial epithelial cells. 
The NFKB Pathway Is Activated in B. pertussis-Infected Cells Without 
Evidence of Apoptosis. Our study of human bronchial epithelial cells 
indicates that activation of NFKB and downstream pathways are 
dominant features of B. pertussis infection, as has been implicated 
in other infections (27, 36). The use of dexamethasone and sodium 
salicylate support this finding, because both inhibit NFKB activa- 
tion, and they abolished the responses of genes which we propose 
were induced by NFKB. TRIP, which inhibits NFKB activation, is 
down-regulated on infection, thereby allowing NFKB activation 
(37). Furthermore, the transcriptional changes in TNFAIP3, API2, 
and BTF are suggestive of antiapoptotic signaling, despite the 
previous findings of B. pertussis-induced apoptosis in monocytes 
and neutrophils (17). In addition, our use of a phenotypic marker 
for apoptosis, the appearance of mono- and oligonucleosomes, 
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revealed no evidence of apoptosis in the infected cells after 3 h. 
Thus, B. pertussis may have evolved specific mechanisms for killing 
inflammatory cells while sparing the nonciliated epithelium on 
which it survives. 
PT-Responsive Genes Present Clues to the Pathogenesis of Pertussis. 
Our use of a catalytically inactive toxin and a strain bearing this 
mutant toxin allowed us to investigate the role of the ADP- 
ribosyltransferase activity of PT without the confounding effects 
of other PT-associated activities. In BEAS-2B cells, two colla- 
genases, fibroblast activation protein and matrix metal- 
loproteinase I (MMP-1) were transcriptionally down-regulated 
by the enzymatic activity of PT. MMP-1 transcription is in- 
creased by other infections (38) and by basic fibroblast growth 
factor (39), whose transcription was increased by PT catalytic 
activity. Down-regulation of MMP-1 expression appears to be an 
active process and one that is unexpected. An examination of the 
responses elicited by this toxin on other cell types will likely 
reveal many other G-protein-linked genes. 
Transcriptional analysis suggests that the quantity and quality 
of respiratory secretions are altered by the ADP-ribosylase 
activity of PT. The product of the down-regulated VIP gene 
increases secretion of Cl- in epithelial cells (40). In the lung, 
serotonin mediates airway reactivity and causes fluid transport 
across the epithelium into the tracheal lumen (41). Serotonin is 
cleared by a transporter, whose gene, SLC6A4, is up-regulated 
by PT. Through these regulatory events, B. pertussis may modify 
the physical properties of the respiratory tract mucus. This is 
borne out by descriptions of thick tenacious mucus at autopsy. 
Inhibition of NFKB Activation by Antiinflammatory Agents Has Ther- 
apeutic Implications. Previous studies have proposed that cortico- 
steroids may have some benefit in the treatment of pertussis 
through their effect on transcription ofproinflammatory effectors 
such as IL-1,B, IL-6, and IL-8 (22). Of particular interest given the 
role of iNOS in epithelial cell pathology (12) was the finding that 
dexamethasone treatment before infection led to increased tran- 
scription of iNOS. Other studies have described a decrease in iNOS 
transcription when cells are treated with corticosteroids before 
stimulation with lipopolysaccharide and several cytokines (42). In 
our study, iNOS transcriptional ctivation occurred despite the 
induction of TNFAIP3 expression; in some cells, TNFAIP3 blocks 
transcription ofiNOS (14). Thus, our data indicate the dominance 
of other positive regulatory factors on iNOS expression. From the 
perspective of disease management, these data may suggest caution 
in the use of corticosteroids for patients with whooping cough. 
These agents are predicted to worsen TCT-mediated induction of 
iNOS and subsequent adverse effects on neighboring ciliated 
epithelial cells. 
B. pertussis Subverts the Mucociliary Escalator. Although mucus is 
often considered a host defense; in some diseases, such as 
asthma, bronchitis, and cystic fibrosis, it contributes to the 
pathology. Our data show that B. pertussis, like many other 
infectious agents or irritants, is capable of inducing mucin 
transcription. With an intact mucociliary escalator, mucin pro- 
vides an important housekeeping function. However, lipopoly- 
saccharide, in combination with TCT of B. pertussis, paralyzes 
ciliated epithelial cells and causes their death and extrusion (6), 
leading to a buildup of respiratory secretions. As described 
above, PT-induced alterations in VIP and serotonin signaling 
could lead to thicker and even more tenacious mucus. We have 
demonstrated that B. pertussis is able to bind to mucin, suggesting 
that the pathogen may be manipulating host defenses to create 
a favorable microenvironment for itself. 
Conclusion. Transcriptional nalysis of infected epithelial cells has 
helped to reveal the mechanisms by which the host responds to B. 
pertussis and some of the mechanisms by which this pathogen 
attempts to subvert host defenses. Our data help to integrate 
preexisting information about the pathology of pertussis, patho- 
gen-host and receptor-ligand interactions, and host cell pheno- 
types, with virulence mechanisms. A more comprehensive xami- 
nation of transcriptional responses of pathogens and their hosts will 
help define conserved and specific strategies used by both. 
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